Late-Onset Retinal Degeneration Clinical Trials

• Able and willing to provide informed consent (or have a legally authorized representative who is able and willing to provide informed consent) prior to any study assessments and procedures and comply with the study requirements and visits.

• Male or female with a diagnosis of CNV secondary to nAMD in the study eye, with nAMD disease activity at Screening Visit 1.

• At least 50 years old at Screening Visit 1.

• An ETDRS BCVA letter score of 35 - 78 (approximate Snellen equivalent of 20/200 to 20/32) in the study eye at Screening Visit 1.

• Demonstrated a meaningful anatomic response to anti-VEGF therapy during screening.

• Able to reliably use eye drops per protocol.